Avenue Therapeutics grants options for 1.05M shares to CEO and Interim CFO

AVENUE THERAPEUTICS, INC.

CEO Alexandra MacLean granted option to purchase 800,000 shares at $1.14/share.
Interim CFO/COO David Jin granted option to purchase 250,000 shares at same price.
Options vest in four equal annual installments beginning August 1, 2023.
Options expire 10 years from grant dates (June 29, 2033 and June 30, 2033).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.